Loss-of-function mutations in the human voltage-gated sodium channel Na V 1.7 result in a congenital indifference to pain. Selective inhibitors of Na V 1.7 are therefore likely to be powerful analgesics for treating a broad range of pain conditions. Herein we describe the identification of μ-SLPTX-Ssm6a, a unique 46-residue peptide from centipede venom that potently inhibits Na V 1.7 with an IC 50 of ∼25 nM. μ-SLPTX-Ssm6a has more than 150-fold selectivity for Na V 1.7 over all other human Na V subtypes, with the exception of Na V 1.2, for which the selectivity is 32-fold. μ-SLPTX-Ssm6a contains three disulfide bonds with a unique connectivity pattern, and it has no significant sequence homology with any previously characterized peptide or protein. μ-SLPTX-Ssm6a proved to be a more potent analgesic than morphine in a rodent model of chemicalinduced pain, and it was equipotent with morphine in rodent models of thermal and acid-induced pain. This study establishes μ-SPTX-Ssm6a as a promising lead molecule for the development of novel analgesics targeting Na V 1.7, which might be suitable for treating a wide range of human pain pathologies.
Loss-of-function mutations in the human voltage-gated sodium channel Na V 1.7 result in a congenital indifference to pain. Selective inhibitors of Na V 1.7 are therefore likely to be powerful analgesics for treating a broad range of pain conditions. Herein we describe the identification of μ-SLPTX-Ssm6a, a unique 46-residue peptide from centipede venom that potently inhibits Na V 1.7 with an IC 50 of ∼25 nM. μ-SLPTX-Ssm6a has more than 150-fold selectivity for Na V 1.7 over all other human Na V subtypes, with the exception of Na V 1.2, for which the selectivity is 32-fold. μ-SLPTX-Ssm6a contains three disulfide bonds with a unique connectivity pattern, and it has no significant sequence homology with any previously characterized peptide or protein. μ-SLPTX-Ssm6a proved to be a more potent analgesic than morphine in a rodent model of chemicalinduced pain, and it was equipotent with morphine in rodent models of thermal and acid-induced pain. This study establishes μ-SPTX-Ssm6a as a promising lead molecule for the development of novel analgesics targeting Na V 1.7, which might be suitable for treating a wide range of human pain pathologies.
chronic pain | drug discovery | peptide therapeutic N ormal pain is a key adaptive response that serves to limit our exposure to potentially damaging or life-threatening events. In contrast, aberrant long-lasting pain transforms this adaptive response into a debilitating and often poorly managed disease. Chronic pain affects ∼20% of the population, with the incidence rising significantly in elderly cohorts (1) . The economic burden of chronic pain in the United States was recently estimated to be ∼$600 billion per annum, which exceeds the combined annual cost of cancer, heart disease, and diabetes (2) . There are few drugs available for treatment of chronic pain, and many of these have limited efficacy and dose-limiting side-effects.
Voltage-gated sodium (Na V ) channels are integral transmembrane proteins that provide a current pathway for the rapid depolarization of excitable cells (1, 3) , and they play a key role in conveying nociceptor responses to synapses in the dorsal horn (4) . Humans contain nine different Na V channel subtypes, denoted Na V 1.1 to Na V 1.9 (5, 6) . In recent years, Na V 1.7 has emerged as a promising analgesic target based on several remarkable human genetic studies. Gain-of-function mutations in the SNC9A gene encoding the pore-forming α-subunit of Na V 1.7 cause severe episodic pain in inherited neuropathies, such as erythromelalgia and paroxysmal extreme pain disorder (7) , whereas loss-of-function mutations in SCN9A result in a congenital indifference to pain (CIP) (8) . The latter phenotype can be recapitulated in rodents via complete knockout of Na V 1.7 in all sensory and sympathetic neurons (9) . Moreover, certain polymorphisms in SCN9A correlate with sensitivity to nociceptive inputs (10) . Remarkably, apart from their inability to sense pain, loss of smell (anosmia) is the only other sensory impairment in individuals with CIP (11, 12) . Thus, the combined genetic data suggest that subtype-selective blockers of Na V 1.7 are likely to be useful analgesics for treating a broad range of pain conditions.
Centipedes are one of the oldest extant arthropods, with the fossil record dating back 430 million y (13) . Centipedes were one of the first terrestrial taxa to use venom as a predation strategy, and they have adapted to capture a wide variety of prey, including insects, fish, molluscs, amphibians, reptiles, and even mammals (13, 14) . The centipede venom apparatus, which is unique and bears little resemblance to that of other arthropods, evolved by modification of the first pair of walking legs into a set of pincerlike claws (forcipules) (13) . Venom is secreted via a pore located near the tip of each forcipule. There are ∼3,300 extant species of centipedes, yet the venom of only a handful has been studied in any detail. We recently demonstrated that the venom of the Chinese red-headed centipede Scolopendra subspinipes mutilans is replete with unique, disulfide-rich peptides that potently modulate the activity of mammalian voltage-gated ion channels (14) , and therefore we decided to explore this venom as a potential source of Na V 1.7 inhibitors. We describe the purification from this venom of a highly selective inhibitor of Na V 1.7 that is a more effective analgesic than morphine in rodent pain models.
Results
Purification of μ-SLPTX-Ssm6a. A unique peptide denoted μ-SLPTXSsm6a (hereafter Ssm6a) was purified from venom of the centipede S. subspinipes mutilans using a combination of Sephadex G-50 gel-
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The economic burden of chronic pain in the United States is currently ∼$600 billion per annum, which exceeds the combined annual cost of cancer, heart disease, and diabetes. Few drugs are available for treating chronic pain, and many have limited efficacy and dose-limiting side-effects. Humans with inheritable loss-of-function mutations in the voltage-gated sodium channel Na V 1.7 are indifferent to all types of pain, and therefore drugs that block this channel should be useful analgesics for treating many pain conditions. Herein we describe Ssm6a, a peptide from centipede venom that potently and selectively blocks the human Na V 1.7 channel. Ssm6a proved to be more analgesic than morphine in rodent pain models and did not cause any side-effects.
filtration chromatography and reverse-phase (RP) HPLC (Fig. 1A) . The primary structure of Ssm6a was determined via Edman degradation in combination with analysis of a venom-gland transcriptome (Fig. 1B) . The 46-residue mature toxin is produced by posttranslational processing of a 111-residue prepropeptide (Fig.  1B) , its mass determined using MALDI-TOF mass spectrometry (5318.4 Da) (Fig. S1) indicates that the six cysteine residues form three disulfide bonds. A BLAST search of the protein/DNA sequence databases revealed that Ssm6a is not similar to any known peptide or protein, except for ∼40% sequence identity with κ-SLPTX-Ssm1a that we recently isolated from the venom of the same centipede (14) .
Partial reduction of native Ssm6a with Tris (2-carboxyethyl) phosphine (TCEP) yielded four peaks when the sample was fractionated using RP-HPLC (Fig. S2) . The mass of peaks II and III were increased by 2 Da and 4 Da, respectively, relative to the native peptide indicating that they contained either one (peak II) or two (peak III) reduced disulfide bonds (Fig. S2) . These partially reduced peptides were alkylated with iodoacetamide then subjected to Edman degradation. Peak II yielded alkylated Cys residues in cycles 5 and 32 (Fig. S3) , indicative of a Cys5-Cys32 disulfide bridge in the native toxin. Sequencing of peak III was inconclusive. Analysis of side-chain/side-chain dipolar connectivities (15) in a 2D 1 H-1 H NOESY spectrum of Ssm6a revealed that the remaining two disulfide bridges are Cys15-Cys31 and Cys18-Cys41 (Fig. 1C) .
Effect of μ-SLPTX-Ssm6a on Na V Channels. Because Na V 1.7 is preferentially expressed in dorsal root ganglia (DRG) and sympathetic neurons (16), we investigated the ability of Ssm6a to block Na V 1.7 channel currents in adult rat DRG neurons using wholecell patch-clamp electrophysiology. Although Na V 1.7 is the most highly expressed Na V channel in DRG neurons, they also express other subtypes, including Na V 1.8 and Na V 1.9.
Cells were held at -80 mV for over 5 min to allow adequate equilibration, then current traces were evoked using a 50-ms step depolarization to -10 mV every second. TTX (100 nM) was added to the bathing solution to separate TTX-resistant (TTX-r) currents from other sodium currents in DRG neurons (17) . Na V 1.5, Na V 1.8, and Na V 1.9 are TTX-r, whereas all other subtypes are TTX-sensitive (TTX-s). TTX-s currents were completely inhibited by 1 μM Ssm6a, whereas 10 μM toxin had no effect on TTX-r currents (Fig. 2A) . Inhibition of TTX-s currents was dose-dependent with an IC 50 of 23 nM (Fig. 2B) . The action of Ssm6a on TTX-s currents was fast, and toxin dissociation was rapid after washing with extracellular solution. Time constants governing block (τ on ) and unblock (τ off ) following exposure to 1 μM Ssm6a were 8.0 s and 10.2 s, respectively.
In the presence of 20 nM Ssm6a, the current-voltage relationship for TTX-s Na V channel currents was shifted ∼15 mV in a depolarizing direction (Fig. 2D) , and consequently the channel conductance-voltage relationship was positively shifted by ∼18 mV (Fig. 2E) . In contrast, Ssm6a did not induce a shift in steady-state inactivation of TTX-s Na V channel currents in DRG neurons (Fig. 2F) . At a saturating concentration of Ssm6a (1 μM), the inhibition of TTX-s currents in rat DRG neurons and HEK293 cells expressing human Na V 1.7 was partly overcome by depolarizations to large positive test potentials (>60 mV) (Fig. S4 ). This partial reversal of channel inhibition, along with the depolarizing shift in the voltage dependence of activation, is characteristic of gating modifiers that interact with the voltage-sensing domains of Na V channels (18) . In contrast, as expected, inhibition of Na V 1.7 currents by the pore-blocker TTX was largely voltage-independent (Fig. S4) .
Selectivity of Ssm6a for Na V Channel Subtypes. We examined the effect of Ssm6a on human (h) Na V channel subtypes 1.1-1.8 expressed in HEK293 cells. Currents were elicited by a 20-ms depolarizing potential of -10 mV from a holding potential of -80 mV every 5 s. At a concentration of 50 nM, Ssm6a potently inhibited hNa V 1.7, decreasing current amplitude by ∼63% (Fig.  3D) . The peptide was a much weaker inhibitor of hNa V 1.1, hNa V 1.2, and hNa V 1.6; at 2 μM, Ssm6a depressed hNa V 1.1 currents ∼by 25% (Fig. 3A) , whereas 1 μM Ssm6a reduced hNa V 1.2 and hNa V 1.6 currents by 31% (Fig. 3B ) and 25% (Fig.  3C ), respectively. The calculated IC 50 values were 4.1 μM, 813 nM, 15.2 μM, and 25.4 nM for hNa V 1.1, hNa V 1.2, hNa V 1.6, and hNa V 1.7, respectively (Fig. 3E) . Ssm6a had no effect on hNa V 1.3, hNa V 1.4, hNa V 1.5, and hNa V 1.8 (Fig. S5) .
Similar to the effect of protoxin-II on rat DRG neurons, Ssm6a shifted the conductance-voltage relationship in a depolarizing direction (19) . Ssm6a shifted the conductance-voltage relationship about +10.7, +12.9, +9.55, and +13.5 mV for hNa V 1.1, hNa V 1.2, hNa V 1.6, and hNa V 1.7, respectively (Fig. 4) . Ssm6a did not induce a shift in steady-state inactivation for these Na V channel subtypes (Fig. 4) .
Notably, the concentration-response curves for Ssm6a inhibition of TTX-s Na V currents in DRG neurons (Fig. 2B ) and hNa V 1.7 currents in HEK293 cells (Fig. 3E ) were rather shallow (Hill coefficient ∼0.5), suggesting that the peptide might interact with multiple sites on Na V 1.7 that exhibit negative cooperativity. Such a mechanism of action would not be unprecedented, because it has been demonstrated that several Na V channel toxins derived from arachnid venoms bind to more than one of the voltage-sensor paddles in Na V 1.2 (19) .
Effects of Ssm6a on Pain. Because Na V 1.7 plays a key role in nociception in humans, the analgesic effect of Ssm6a was tested in several rodent pain models in which pain was induced by noxious chemicals, acid, or heat.
Intraplantar injection of formalin leads to a biphasic pain response in mice: an early nociceptive response (phase I, 0-5 min) caused by direct stimulation of TRPA1 in a subpopulation of Cfiber nociceptors is followed by a quiescent period that precedes a second phase of nociceptive behavior (phase II, 15-30 min) because of peripheral inflammation together with central sensitization (20) . Intraperitoneal injection of Ssm6a drastically decreased both phase I and phase II responses (Fig. 5A ). Control mice (saline injection) licked their paws an average of 212 times during phase I. Ssm6a was highly effective at attenuating phase I pain, with the number of paw licks reduced by 14%, 60%, and 92% at peptide concentrations of 1, 10, and 100 nmol/kg, respectively (Fig. 5A ). On a molar basis, Ssm6a was significantly more effective than morphine, which reduced the number of paw licks during phase I by 3%, 19%, and 69% at concentrations of 1, 10, and 100 nmol/kg, respectively (Fig. 5A) .
Ssm6a was also highly effective at attenuating the second phase of nociceptive behavior following formalin injection, during which control mice licked their paws an average of 694 times. At concentrations of 1, 10, and 100 nmol/kg, Ssm6a decreased the number of paw licks during phase II by 25%, 54%, and 80%, respectively (Fig. 5B) . On a molar basis, Ssm6a was significantly more effective than morphine, which reduced the number of paw licks during phase II by 3%, 16%, and 57% at concentrations of 1, 10, and 100 nmol/kg, respectively (Fig. 5B) .
Ssm6a was as effective as morphine in reducing abdominal writhing induced in mice by intraperitoneal injection of acid (Fig.  5C ). At concentrations of 1, 10, and 100 nmol/kg, Ssm6a decreased the number of writhing movements by 29%, 51%, and 79%, respectively (Fig. 5C ), which is similar to the reductions of 25%, 44%, and 76% caused by equivalent concentrations of morphine (Fig. 5C ).
Ssm6a and morphine were similarly effective at reducing thermal pain (Fig. 5D ). In mice subjected to photothermal heat, tail withdrawal latency was increased from 5 s in the saline-treated control group to 6.3 s, 9.2 s, and 13.4 s in mice treated with 1, 10, and 100 nmol/kg Ssm6a, respectively. Similar increases in paw withdrawal latency were observed for mice treated with the same concentrations of morphine (Fig. 5D ).
Side-Effect Profile. At doses up to 10-fold higher than those for which we observed robust analgesic effects, Ssm6a had no evident side effects. At a dose of 1 μmol/kg, Ssm6a had no effect on blood pressure (Fig. S6A ), heart rate ( Fig. S6B ), or motor function (Fig. S6C) .
Plasma Stability and Duration of Action of Ssm6a. Ssm6a must be highly stable in vivo because it drastically reduced nociceptive behavior in phase II of the formalin-induced pain model, the onset of which occurred ∼45 min after intraperitoneal injection of the peptide. Consistent with this hypothesis, Ssm6a was found to be extraordinarily stable in isolated human plasma, with no significant degradation over 1 wk, compared with a half-life of 64 min for rat atrial natriuretic peptide under the same conditions (Fig. 6A) . However, the analgesic effect of Ssm6a declined monotonically over a period of 4 h in rodent models of acid-and heat-induced pain, as well as phase I of the formalin pain model. Interestingly, at the highest doses tested, Ssm6a still produced robust analgesic effects after 4 h in phase II of the formalin pain model. The major factor determining systemic concentrations of Ssm6a, and thus the time course of its analgesic efficacy, is likely to be the rate at which it is cleared by the liver and kidney (21) .
Because of its unique amino acid sequence and disulfide framework, we propose that Ssm6a has a unique 3D structure. Consistent with this hypothesis, the far-UV CD spectrum of Ssm6a (Fig. 6B ) revealed that it is predominantly α-helical, in striking contrast to all other venom peptides that target Na V channels whose primary secondary structure elements are two to three β-strands. This unusual 3D-fold not only provides Ssm6a with a high level of resistance to proteases, as evidenced by its stability in human plasma, but it also provides it with unusually high thermal stability. We were unable to obtain complete thermal unfolding curves for Ssm6a in the absence of a chemical denaturant; even in 4 M urea, the peptide was only ∼50% unfolded at 90°C (Fig. 6C) . The estimated midpoint (T m ) of the thermal unfolding transition for Ssm6a in 8 M urea was 70.6 ± 0.1°C (Fig. 6C) .
Discussion
Clinical genetic studies have identified hNa V 1.7 as a critical mediator of pain sensitization (7). Loss-of-function mutations in hNa V 1.7 cause a congenital indifference to pain with no other sensory impairments except anosmia (8, 22, 23) , whereas gain-offunction mutations are associated with painful neuropathies (7, 24) . Ablation of Na V 1.7 in all mouse sensory neurons abolishes mechanical pain, inflammatory pain, and reflex withdrawal responses to heat, without affecting neuropathic pain. However, ablation of Na V 1.7 in both sensory and sympathetic neurons abolishes all pain sensations and recapitulates the pain-free phenotype seen in CIP patients (9) . Thus, Na V 1.7 appears to be an attractive target for the development of novel analgesics for treating a wide range of pain pathologies.
Development of Na V 1.7-based analgesics has proved difficult, as it is essential to avoid off-target effects on closely related Na V channels with critical physiological roles. In particular, it is essential to avoid off-target effects on hNa V 1.5, which is responsible for the rising phase of the cardiac action potential (25) , the muscle-specific hNa V 1.4, and hNa V 1.6, the primary Na V channel at nodes of Ranvier (26) .
Spider venoms have proved to be a rich source of Na V 1.7 channel inhibitors (27) , but most spider-venom peptides isolated to date are not sufficiently selective to be therapeutically useful. For example, although protoxin-II blocks hNa V 1.7 with extremely high affinity (IC 50 ∼300 pM), it is also a high-affinity inhibitor of hNa V 1.2 (IC 50 ∼41 nM), hNa V 1.5 (IC 50 ∼79 nM), and hNa V 1.6 (IC 50 ∼26 nM) (27) . Because of its lack of selectivity, protoxin-II proved lethal to rats when administered intravenously at a dose of 1.0 mg/kg or intrathecally at 0.1 mg/kg (28) . Although several small-molecule blockers of hNa V 1.7 have been described, they generally suffer from a similar lack of subtype selectivity (25, 29) .
In this study we examined centipede venom as a potential source of selective Na V 1.7 inhibitors because we previously demonstrated that these venoms are replete with ion channel modulators (14) . We described the purification and functional characterization of a unique peptide (Ssm6a) with potent analgesic properties from venom of the centipede S. subspinipes mutilans. Ssm6a contains 46-residues with three disulfide bonds and it has no significant homology with any previously described protein or peptide. The disulfide linkage pattern (C1-C5, C2-C4, C3-C6) is notably to different to that of the inhibitor cystine knot motif (C1-C4, C2-C5, C3-C6) found in most spider-venom peptides that modulate Na V channels (27) (Fig. 1C) . Moreover, Ssm6a is predominantly α-helical, in striking contrast to other venom peptides that target Na V channels. Despite its unique 3D architecture, both the thermal stability and protease resistance of Ssm6a are reminiscent of spider-venom inhibitor cystine knot peptides (30) .
Ssm6a is the most subtype-selective inhibitor of Na V 1.7 reported to date. Ssm6a selectively inhibits hNa V 1.7 with an IC 50 of 25 nM (Fig. 3 D and E) by shifting the voltage-dependence of activation to more depolarized potentials (Fig. 4D) , but it has no effect on hNa V 1.3, hNa V 1.4, hNa V 1.5, and hNa V 1.8, and only inhibits hNa V 1.1, hNa V 1.2, and hNa V 1.6 at very high concentrations. Most importantly from a therapeutic perspective, Ssm6a has 600-fold or higher selectivity for Na V 1.7 over the key off-target subtypes Na V 1.4, Na V 1.5, and Na V 1.6, and it has no effect on hERG (K V 11.1) at concentrations up to 10 μM (Fig. S7) .
Consistent with its potent and highly selective block of Na V 1.7, Ssm6a proved to be an effective analgesic in rodent pain models (Fig. 5) . On a molar basis, Ssm6a was several-fold more effective than morphine in a rodent model of formalin-induced pain (Fig.  5 A and B) and it was equipotent with morphine in its ability to reduce thermal and acid-induced pain (Fig. 5 C and D) . Ssm6a is highly stable in human plasma, and intraperitoneal administration of the peptide at doses up to 1 μmol/kg produced no adverse effects on blood pressure, heart rate, or motor function. Thus, Ssm6a appears to be an excellent lead molecule for development of analgesics targeted against hNa V 1.7. However, future experiments should be directed toward examination of the analgesic activity of Ssm6a in more complex rodent pain models that better resemble human pain phenotypes, as well as a more detailed assessment of its selectivity for the nociceptive circuitry.
Finally, we speculate that the biological role of Ssm6a in centipede venom is likely to be block of Na V channels in insect Fig. 4 . Effect of Ssm6a on current-voltage relationships. Ssm6a induced a depolarizing shift in the I-V curves for activation of (A) hNa V 1.1 (10.7-mV shift at 10 μM), (B) hNa V 1.2 (12.9-mV shift at 1 μM), (C) hNav1.6 (9.5-mV shift at 5 μM), and (D) hNav1.7 (13.5-mV shift at 20 nM). In contrast, the peptide had no effect on steady-state inactivation of these channels (A-D). prey. In contrast to humans, insects express only a single Na V channel that is a common target of peptides in the venom of arthropod predators, such as spiders and scorpions (6) . Ssm6a blocks hNav.1.7 within seconds of administration (Fig. 2C) , and a similarly rapid block of insect Na V channels would induce rapid paralysis and ultimately death of insect prey. The species from which Ssm6a was purified belongs to Scolopendromorpha, one of the five extant orders of centipedes (13) , and thus it will be interesting from a toxinological perspective to determine whether this unusual class of toxins is unique to this order or represents a more basal recruitment within the centipede phylogenetic tree.
Although it might seem counterintuitive that a venom peptide used for predation could be a useful therapeutic, the significant differences in primary structure and tissue distribution between insect and human ion channels makes this possible. There are now six Food and Drug Administration-approved drugs derived from venom peptides or proteins, with many more in clinical trials or various stages of preclinical development (21) . The approved group includes Prialt, a Ca V 2.2 blocker from the venom of a marine cone snail that is used for treatment of severe intractable pain (21) . The present study suggests that centipede venoms, which to date have been largely neglected, might provide a novel source of lead molecules for drug development.
Materials and Methods
Assignment of the Disulfide Bonds. Ssm6a (0.1 mg) was partially reduced in 10 μL of citrate buffer (1 M, pH 3.0) containing 6 M guanidine·HCl and 0.05 M TCEP for 10 min at 40°C. The partially reduced sample was fractionated via C 18 RP-HPLC using a linear acetonitrile gradient (0-60% over 40 min). Intermediates with free thiols (as determined using MALDI-TOF mass spectrometry) were lyophilized and alkylated with iodoacetamide (0.5 M, pH 8.3). Alkylated peptides were desalted using C 18 RP-HPLC then subjected to Edman degradation on a Shimadzu protein sequencer (PPSQ-31A; Shimadzu).
Patch-Clamp Recording on Rat DRG Neurons. Rat DRG neurons were acutely dissociated and maintained in short-term primary culture, as previously described (31) . Ca 2+ , Na + , and K + currents were recorded using the whole-cell patch-clamp technique with an Axon Multiclamp 700B amplifier (Molecular Devices). The P/4 protocol was used to subtract linear capacitive and leakage currents. Series resistance was typically 6-8 mΩ and was compensated to 80% (32) . Data were acquired and analyzed using Clampfit 10.0 (Molecular Devices) and SigmaPlot (Systat Software). All animal experiments described in this work were approved by the Animal Care and Use Committee at Kunming Institute of Zoology, Chinese Academy of Sciences (2011-162).
Patch-Clamp Recordings on Human Na V Channels. Human Na V 1 α-subunits, the human Na V β1 subunit, and eGFP were transiently transfected into HEK293T cells and whole-cell patch-clamp recordings performed as previously described (33) . The standard pipette solution contained: 140 mM CsF, 1 mM EGTA, 10 mM NaCl, 3 mM KCl, and 10 mM MgCl 2 , pH 7.3. The standard bath solution was: 140 mM NaCl, 3 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2, and 10 mM Hepes, pH 7.3. Data were acquired and analyzed using Clampfit 10.0 and SigmaPlot. All datapoints are shown as mean ± SE (n = number of separate experimental cells examined). Dose-response curves were fitted using the following Hill logistic equation:
where n is an empirical Hill coefficient and f max is the fraction of current resistant to inhibition at high toxin (Tx) concentration. Steady-state activation and inactivation curves were fitted using the Boltzmann equation:
, V, and k represented midpoint voltage of kinetics, test potential and slope factor, respectively. τ on and τ off values were obtained from single exponential fits using the equations I(t) = a 0 + a 1 [1 -exp(-t/τ on )] and I(t) = a 0 + a 1 exp(-t/τ off ), respectively. Thermal Pain Test. A photothermal pain detector (YLS-12A; Jinan) was used to measure the pain threshold of mice subjected to intense heat (34) . The light beam of the detector was focused on the middle portion of the tail, and mice measured to have a tail withdrawal latency of 4-6 s were selected for the tail-flick test. Test animals were injected intraperitoneally with 100 μL saline containing Ssm6a or morphine 30 min before photothermal heating of the tail. The control group received the same volume of saline. Tail withdrawal latency was measured as the time taken to withdraw the tail from the light beam.
Abdominal Writhing Induced by Acetic Acid. Mice were injected intraperitoneally with 100 μL saline containing Ssm6a or morphine 30 min before intraperitoneal injection of 200 μL 0.8% (vol/vol) acetic acid, which induces abdominal contractions and hind limb stretching (35) . The control group received the same volume of saline. Mice were placed into open polyvinyl cages (20 × 40 × 15 cm) immediately after acid challenge, and abdominal constrictions were counted cumulatively over a period of 30 min.
Recombinant Peptide Production. Recombinant Ssm6a was produced via expression in the periplasm of Escherichia coli as described for the spidervenom peptide PcTx1 (36) . Further details are provided in SI Materials and Methods (Fig. S8) . Note that native toxin was used for all electrophysiological and animal studies.
Plasma Stability. Lyophilized human plasma (Sigma-Aldrich, batch 101M7025) was resuspended in an equivalent volume of ultrapure water, then lyophilized recombinant Ssm6a or rat atrial natriuretic peptide (American Peptide Company, Cat. No. 14-5-41) was added to a final concentration of 20 μM and samples were incubated at 37°C for 7 d. Triplicate samples were taken at selected time points, quenched by addition of urea, then plasma proteins were precipitated with 20% (vol/vol) trichloroacetic acid. Samples were centrifuged at 14,900 × g for 15 min, then supernatants were fractionated via C 18 RP-HPLC. The peak corresponding to intact Ssm6a was identified by coelution with native toxin and mass determination via MALDI-TOF mass spectrometry using α-cyano-4-hydroxycinnamic acid matrix on a 4700 Proteomics Bioanalyzer (Applied Biosystems). Ssm6a levels were then quantified from peak absorbance at 214 nm.
CD Spectropolarimetry. CD spectra of Ssm6a (20 μM in 10 mM KHPO 4 , pH 7.2) were acquired at 20°C under constant N 2 flush using a Jasco J-810 spectropolarimeter. Spectra were the sum of eight scans acquired over the region 260-190 nm at 20 nm/min. Percent helicity was determined from the mean residue ellipticity at 222 nm (θ 222 ), as described previously (37) . Thermal denaturation profiles were obtained by monitoring θ 222 as the temperature was increased from 20 to 95°C at a rate of 2°C/min. Denaturation curves were fitted with a six parameter sigmoidal function (38) to obtain T m values. The thermal denaturation of Ssm6a was completely reversible upon cooling.
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Yang et al. 10 .1073/pnas.1306285110 SI Materials and Methods Venom Collection and Neurotoxin Purification. Adult Scolopendra subspinipes mutilans L. Koch (both sexes, n = 3,000) were purchased from Jiangsu Province, China. Venom was collected manually by stimulating the venom glands, which are located within the first pair of modified legs, known as forcipules or maxillipeds (1), with a 3-V alternating current. Each milking occurred 1 wk after the previous milking. The unique peptide toxin was purified from the venom using a combination of gel filtration and reverse-phase (RP) HPLC, and stored at -20°C until further use.
Mass Spectrometry. The μ-SLPTX-Ssm6a (hereafter Ssm6a) was dissolved in 0.1% (vol/vol) trifluoroacetic acid (TFA)/water and 0.5 μL was spotted onto a MALDI-TOF plate with 0.5 μL α-cyano-4-hydroxycinnamic acid (CHCA) matrix [10 mg/mL in 60% (vol/vol) acetonitrile]. Spots were analyzed using an UltraFlex I mass spectrometer (Bruker Daltonics) in positive ion mode.
Peptide Sequencing. The complete amino acid sequence of purified neurotoxin was determined by Edman degradation using a pulsed liquid-phase Shimadzu protein sequencer (PPSQ-31A, Shimadzu) according to the manufacturer's instruction.
cDNA Library and Cloning. Total RNA was extracted from the venom glands of 20 centipedes using TRIzol (Life Technologies) and used to prepare cDNA using a SMART PCR cDNA synthesis kit (Clontech). The first strand was synthesized using the 3′ SMART CDS Primer II A [5′ AAGCAGTGGTATCAACGCAGAGTACT (30)N -1 N 3′, where n = A, C, G, or T and N -1 = A, G, or C] and SMART II A oligonucleotide, (5′ AAGCAGTGGTATCAAC-GCAGAGTACGCGGG 3′). The 5′ PCR primer II A (5′ AAG-CAGTGGTATCAACGCAGAGT 3′) provided in the kit was used to synthesize the second strand using Advantage polymerase (Clontech). A directional cDNA library was then constructed with a plasmid cloning kit (SuperScriptTM Plasmid System, GIBCO/ BRL) following the manufacturer's instructions. The resultant cDNA library comprised 2.2 × 10 5 independent colonies. A PCR-based method for high stringency screening of DNA libraries was used for screening and isolating cDNA clones. The sense-direction primer was designed according to the amino acid sequence determined by Edman degradation 5′-
The primer was used in conjunction with an antisense SMART II A primer II in PCR to screen for transcripts encoding the neurotoxin. PCR was performed using Advantage polymerase (Clontech) using the following conditions: 2 min at 94°C, followed by 30 cycles of 10 s at 92°C, 30 s at 50°C, 40 s at 72°C. Finally, the PCR products were cloned into the pGEM-T Easy vector (Promega). DNA sequencing was performed on an ABI PRISM 377 DNA sequencer (Applied Biosystems).
hERG Assays. Xenopus laevis oocytes were injected with cRNA encoding the hERG channel then incubated at 17°C in 96 mM NaCl, 2 mM KCl, 5 mM Hepes, 1 mM MgCl 2 , and 1.8 mM CaCl 2 , 50 μg/ mL gentamycin, pH 7.6 with NaOH. hERG currents were examined at room temperature (∼22°C) 1-2 d after cRNA injection via two-electrode voltage-clamp techniques (Axoclamp 900A; Molecular Devices) using a 90-μL recording chamber. Data were low pass filtered at 2 kHz and digitized at 10 kHz using pCLAMP 10 (Molecular Devices). Microelectrode resistances were 0.1-1 MΩ when filled with 3 M KCl. The external recording solution comprised 96 mM NaCl, 2 mM KCl, 5 mM Hepes, 2 mM MgCl 2 , 1 mM CaCl 2 , pH 7.6. Oocytes were voltage clamped at a holding potential of -80 mV, and 1-s pulses to a test potential of 0 mV were applied every 12.5 s until the current magnitude reached a steadystate level. After baseline recordings, the bath solution was displaced with 100 μL of test solution and recording continued until a new steady-state level was achieved. The spider-venom peptide VSTX1, a known inhibitor of hERG, was used as a positive control (2) . Data analysis was performed using pCLAMP 10, Prism5 (Graphpad Software), and Microsoft Solver (Microsoft Excel).
Recombinant Production of μ-SLPTX-Ssm6a. Recombinant Ssm6a was produced via expression in the periplasm of Escherichia coli, as reported previously for the spider-venom peptide PcTx1 (3), with minor modifications. A synthetic gene encoding μ-SLPTXSsm6a, with codons optimized for high-level expression E. coli, was synthesized and inserted into the pLicC-MBP vector (4) by GeneArt (Life Technologies). This vector (pLicC-EU2) encodes a MalE signal sequence for periplasmic export, a His 6 affinity tag for protein purification, a maltose binding protein (MBP) fusion tag for increased solubility (5), and a tobacco etch virus (TEV) protease recognition site preceding the Ssm6a gene. The last residue of the TEV cleavage site was altered to match the first residue of Ssm6a so that cleavage of the fusion protein by TEV yields the native sequence.
E. coli strain BL21(λDE3) was transformed with pLicC-EU2 and grown in Luria-Bertani medium at 37°C with shaking at 160 rpm. Cultures were cooled to 16°C and toxin expression was induced with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) at an OD 600 of 1.5-2.0 (Fig. S8, Inset) . Cells were harvested 12 h later by centrifugation then lysed at 26 kPa using a constantpressure cell disruptor (TS Series Benchtop Cell Disrupter, Constant Systems). The His 6 -MBP-toxin fusion protein was then captured by passing the soluble cell fraction over a Ni-NTA Superflow resin (Qiagen). Recombinant Ssm6a was obtained by cleaving the fusion protein with TEV protease at a concentration of 0.2 mg/mL in a redox buffer comprising 40 mM Tris, 400 mM NaCl, 0.6 mM reduced glutathione (GSH), 0.4 mM oxidized GSH, pH 8. Residual fusion protein was precipitated with 1% TFA before the liberated Ssm6a was purified to >95% purity via RP-HPLC (C 18 column; Restek) using a gradient of 15-40% solvent B [0.043% TFA in 90% (vol/vol) acetonitrile] in solvent A (0.05% TFA in water) over 30 min (Fig. S8) .
The identity of the recombinant Ssm6a was confirmed via MALDI-TOF mass spectrometry with CHCA matrix on a 4700 Proteomics Bioanalyzer (Applied Biosystems), and by coelution with native Ssm6a on RP-HPLC (Onyx Monolithic C 18 column; Phenomenex). The final yield of Ssm6a was 2.5 mg/L of culture.
Ssm6a Safety Profiling. Groups of five mice were injected intraperitoneally with 1 μmol/kg Ssm6a or the same volume of saline. Blood pressure and heart rate were measured as we described previously (6) . A swimming exercise performance test was performed as described previously (7) to examine the effect of Ssm6a on motor function. Mice were injected intraperitoneally with saline or Ssm6a (10, 100, 1,000, or 10,000 nmol/kg); the swim test was initiated 30 min after injection. S4 . Ssm6a is a gating modifier. The toxin concentrations used in these experiments were 1 μM Ssm6a and 500 nM TTX. Current-voltage relationships for (A) rat dorsal root ganglia (DRG) neurons (n = 8 cells) and (B) hNa V 1.7 currents in HEK293 cells (n = 12 cells). At a saturating concentration of Ssm6a (1 μM), the inhibition of TTX-s currents in DRG neurons and HEK293 cells expressing hNa V 1.7 was partly overcome by depolarizations to large positive test potentials (>60 mV). In contrast, inhibition of Na V 1.7 currents by the pore-blocker TTX was largely voltage-independent. Fig. S5 . Effect of Ssm6a on selected Na V channel subtypes. Ssm6a (10 μM, red traces) had no effect on currents mediated by (A) hNa V 1.3, (B) hNa V 1.4, (C) hNa V 1.5, or (D) hNa V 1.8. Fig. S7 . Ssm6a has no effect on human ERG (Kv11.1) channels expressed in Xenopus oocytes. Representative K + currents before (black) and after addition of Ssm6a (10 μM, red) or the positive control peptide VSTX1 (30 μM, gray). The voltage-clamp protocol is shown above the current traces. Ssm6a had no effect on the outward activating current or the deactivating tail current of hERG channels (n = 3). 
